Impedimed Limited
ASX:IPD ISIN:AU000000IPD8
ImpediMed Limited (ASX:IPD) is an Australian-based company, which is a global provider of medical technology to measure, monitor and manage fluid status and body composition. The principal activities of the Company consist of the development, manufacture and sale of bioimpedance instruments and consumables, and the sale of electronic test and measurement devices. The Company's operating segments include Medical, and Test & Measurement. The Medical segment is a supplier of non-invasive medical devices to over two underserved markets: aiding in the subclinical assessment of individuals at risk of secondary lymphedema, and the monitoring of body composition and hydration. The medical cash-generating unit (CGU) is the core business of the Company. The Test & Measurement segment is a supplier of power precision testing and measuring equipment (T&M). The Company's geographical locations include Australia/rest of world (ROW) and North America.
News
Australian and New Zealand biotech investors are set to hear from a top line up of speakers from ASX-listed life science companies, as well as several private firms and international businesses, in July, at the 11th Bioshares Biotech Summit.
Benitec Limited (ASX:BLT) (PINK:BNIKF) announced today that Ms Sue MacLeman will step down from the role of Chief Executive Officer (CEO) and Managing Director to pursue other opportunities. She has agreed however to stay actively involved with Benitec as a Strategic Advisor at this exciting time for the Company. A transition arrangement has been put in place. Mr Mel Bridges and Dr John Chiplin will both move to Executive Director roles within the Company and the Board will be further strengthened in the coming months.
ImpediMed Limited (ASX:IPD) would like to bring to the attention of all shareholders the publication: "Incidence, Treatment Costs, and Complications of Lymphedema After Breast Cancer Among Women of Working Age: A 2-Year Follow-Up Study", published on the 16th March 2009 in the online edition of the Journal of Clinical Oncology1.
Impedimed Limited (ASX: IPD) - Company Update from US - Mr Greg Brown, CEO and MD; Impedimed Limited (ASX: IPD) present the following audio webcast regarding "IPD - Company Update from US - Mr Greg Brown, CEO and MD". You may also download this audio webcast to your computer or portable audio player.
Impedimed Limited (ASX: IPD) - Completes US Acquisition of Xitron Technologies - Mr Greg Brown, CEO and MD; Impedimed Limited (ASX: IPD) present the following audio webcast regarding "Completes US Acquisition of Xitron Technologies".
###
5,118 COMPANY PROFILE VIEWS
- This Page Viewed: (Last 7 Days: 7) (Last 30 Days: 28) (Since Published: 5118)
